FDA has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythemia), in adults with anemia.
On May 30, an international coalition announced the launch of CAR T Vision, a coalition that aims to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy.Â
